Sarepta FDA FDA Generation Therapy Are Comment on Elevidys

Shares Saretta therapeutic More than 30% on Friday, the future of the treatment of approved gene therapy is 30% on Friday for the future.

Elevidys, the company, the company, Elevidys, Elevidys, Elevidys, Elevidys, Elevidys, will demand all cargo transportation.

Sarepta said he did not hear from FDA to CNBC.

Separately, FDA Commissioner Marty Makary Bloomberg told the news The agency considers the company’s gene therapy stay in the market.

The FDA investigates two patients with the elevides. The company also also stated a third death in an experimental gene therapy.

Elevidys have even caused even arguing since the confirmation. Gen therapy should clearly prove that Duchenne can benefit people with muscle dystrophy, which contains muscle function in time.

People with disease lose their ability to finally walk and die the most in the early 1920s, it does not need a great treatment. In 2023, FDA first gave a condition for patients for patients only 4 and 5 years of age for patients, the most beneficial groups in clinical trials.

The next year the agency was a full agreement for 4 or greater patients for patients who can walk 4 or more. The last decision was especially controversial, because Elevidys had a proof that could help people so much.

Moreover, Elevidys could not meet a phase 3 trial, although the company claimed that the company had promised other sizes. Then the FDA’s Biology Approval and Research Center head of Peter Marx agreed with Sarepta’s assessment and expanded Elevidys.

The company’s fund fell more than 87% this year.

– CNBC’s Angelica Peebles contributed to this report

This story is developing. Please check again for updates.